Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Lynn

Showing results (41-50 of 240) with videos related to

Pageof 24
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Standard and Genomic Tools for Decision Support in Breast Cancer TreatmentN Lynn Henry, Philippe L Bedard, Angela DeMichele
The Breast Journal|July 6, 2019
Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomyMei Wei, Kathryn A Maurer, N Lynn Henry
Oncology (Williston Park, N.Y.)|December 18, 2008
Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for managementN Lynn Henry, Jon T Giles, Vered Stearns
Breast Cancer Research and Treatment|June 9, 2016
Associations between metabolic syndrome, breast cancer recurrence, and the 21-gene recurrence score assayJeanette Muniz, Kelley M Kidwell, N Lynn Henry
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2021
Evaluating the Association of Adverse Events and Patient-Reported Symptoms to Endocrine Therapy TolerabilityN Lynn Henry, André Rogatko, Patricia A Ganz
JCO Oncology Practice|August 12, 2020
Management of Aromatase Inhibitor-Induced Musculoskeletal SymptomsArjun Gupta, N Lynn Henry, Charles L Loprinzi
Oncology (Williston Park, N.Y.)|February 4, 2010
CYP2D6 testing for breast cancer patients: is there more to the story?N Lynn Henry, Daniel F Hayes, James M Rae
JNCI Cancer Spectrum|April 12, 2021
Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated ArthralgiasPatrick M Schnell, Maryam B Lustberg, N Lynn Henry
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2014
Assessment of PIK3CA mutations in human epidermal growth factor receptor 2-positive breast cancer: clinical validity but not utilityN Lynn Henry, Anne F Schott, Daniel F Hayes
BJU International|May 3, 2000
The short-term prostate-specific antigen velocity before biopsy can be used to predict prostatic histologyN N Lynn, G N Collins, P H O'Reilly
Pageof 24

Showing results (41-50 of 240) with videos related to

Sort By:
Pageof 24
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Standard and Genomic Tools for Decision Support in Breast Cancer TreatmentN Lynn Henry, Philippe L Bedard, Angela DeMichele
The Breast Journal|July 6, 2019
Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomyMei Wei, Kathryn A Maurer, N Lynn Henry
Oncology (Williston Park, N.Y.)|December 18, 2008
Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for managementN Lynn Henry, Jon T Giles, Vered Stearns
Breast Cancer Research and Treatment|June 9, 2016
Associations between metabolic syndrome, breast cancer recurrence, and the 21-gene recurrence score assayJeanette Muniz, Kelley M Kidwell, N Lynn Henry
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2021
Evaluating the Association of Adverse Events and Patient-Reported Symptoms to Endocrine Therapy TolerabilityN Lynn Henry, André Rogatko, Patricia A Ganz
JCO Oncology Practice|August 12, 2020
Management of Aromatase Inhibitor-Induced Musculoskeletal SymptomsArjun Gupta, N Lynn Henry, Charles L Loprinzi
Oncology (Williston Park, N.Y.)|February 4, 2010
CYP2D6 testing for breast cancer patients: is there more to the story?N Lynn Henry, Daniel F Hayes, James M Rae
JNCI Cancer Spectrum|April 12, 2021
Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated ArthralgiasPatrick M Schnell, Maryam B Lustberg, N Lynn Henry
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2014
Assessment of PIK3CA mutations in human epidermal growth factor receptor 2-positive breast cancer: clinical validity but not utilityN Lynn Henry, Anne F Schott, Daniel F Hayes
BJU International|May 3, 2000
The short-term prostate-specific antigen velocity before biopsy can be used to predict prostatic histologyN N Lynn, G N Collins, P H O'Reilly
Pageof 24